T
48
3
HST
39
-3
CTAS
53
-3
AA
56
15
MTB
65
-2
VRTX
47
-6
AON
54
2
SCHW
62
-2
PCAR
56
-5
CHD
54
4
ICE
59
-3
CAH
48
-6
RL
69
-4
XYL
35
-2
SWKS
38
-2
BDX
56
10
COP
57
-2
ROP
53
-9
HBI
58
3
TDC
67
-4
T
48
3
HST
39
-3
CTAS
53
-3
AA
56
15
MTB
65
-2
VRTX
47
-6
AON
54
2
SCHW
62
-2
PCAR
56
-5
CHD
54
4
ICE
59
-3
CAH
48
-6
RL
69
-4
XYL
35
-2
SWKS
38
-2
BDX
56
10
COP
57
-2
ROP
53
-9
HBI
58
3
TDC
67
-4
Financhill
Back

Apellis Pharmaceuticals 10K Form

Sell
33

APLS
Apellis Pharmaceuticals

Last Price:
26.19
Seasonality Move:
20.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $396.59M
Cash Flow: $34.1M
Price / Cash Flow: 0
Annual Sales: $1.94
Price / Book: 13.78

Profitability

EPS (TTM): -2.03000
Net Income (TTM): $-250.1M
Gross Margin: $338.08M
Return on Equity: -104.65%
Return on Assets: -29.46%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for APLS is 85.25%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 126.28% of Gross Profit Margin.
  • The Research & Development expenses have been 89.36% of Revenue.
  • The Interest Expense is -5.60% of Operating Income.
  • The Net Earning history of APLS is -133.29% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 1.91
Current Ratio: 4.36
Quick Ratio: 3.56

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

APLS Technical Analysis vs Fundamental Analysis

Sell
33
Apellis Pharmaceuticals (APLS) is a Sell

Is Apellis Pharmaceuticals a Buy or a Sell?